SCHEMBL4360554

SCHEMBL4360554

CCCCNc1ncnc2ccc(-c3ccc(NC(C)=O)cc3)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.56
ALDH1A1 P00352 9/20 0.56
HSD17B10 Q99714 9/20 0.56
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56
BRAF P15056 3/20 0.56
RAF1 P04049 2/20 0.56
CLK4 Q9HAZ1 10/20 0.55
CYP3A4 P08684 10/20 0.55
CYP2D6 P10635 6/20 0.55
CYP2C19 P33261 6/20 0.55
USP2 O75604 5/20 0.55
LMNA P02545 3/20 0.55
TDP1 Q9NUW8 1/20 0.55
TSHR P16473 5/20 0.52
HIF1A Q16665 4/20 0.52
MAPK1 P28482 1/20 0.51
CLK1 P49759 1/20 0.50
PIK3CA P42336 1/20 0.49
PIK3CG P48736 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353253 0.93 CYP1A2 (0.58) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4355740 0.86 CYP1A2 (0.55) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4359552 0.83 TRIM58 (0.53) ALDH1A1HSD17B10BRAFRAF1LMNA
SCHEMBL4358453 0.83 TLR7 (0.51) CYP3A4CYP2D6
SCHEMBL4351404 0.81 MAP4K4 (0.60) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4367851 0.81 RAF1 (0.59) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4353570 0.81 CLK1 (0.56) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL3336347 0.81 RAB9A (0.53) CYP1A2HPGDBRAFRAF1LMNA
SCHEMBL4366069 0.77 CYP1A2 (0.67) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL3339885 0.77 RAB9A (0.54) BRAFRAF1LMNATDP1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 CYP1A2 1131/4885ALDH1A1 2743/4885HSD17B10 1268/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 CYP1A2 1131/4885ALDH1A1 2743/4885HSD17B10 1268/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 CYP1A2 1129/4885ALDH1A1 2942/4885HSD17B10 1102/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 CYP1A2 1078/4885ALDH1A1 3119/4885HSD17B10 1177/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 CYP1A2 1078/4885ALDH1A1 3119/4885HSD17B10 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.